Can your dentist predict your future health?
Dentistry has evolved far beyond cleaning teeth and filling cavities. Thanks to advancements in technology, particularly predictive analytics, dentists are now stepping into a broader role in healthcare. By analyzing your oral health data, they can detect patterns and risks that offer insight into your overall well-being, sometimes even before symptoms arise.
Predictive analytics is a form of data analysis that uses current and historical information to forecast future outcomes. In dentistry, this means evaluating a combination of dental records, X-rays, lifestyle habits, and medical history to identify early indicators of both oral and systemic health concerns. The approach shifts dentistry from reactive treatment to proactive prevention, allowing issues to be addressed long before they escalate.
Also read: AI and dentistry: How artificial intelligence is shaping personalized oral care
This is especially important given the close relationship between oral health and general health. The mouth often reflects the body's internal conditions. Dentists are frequently among the first to spot signs of systemic diseases such as diabetes, heart disease, osteoporosis, and even certain cancers. For instance, persistent gum inflammation may indicate cardiovascular issues or uncontrolled blood sugar, well before a patient is formally diagnosed.
HOW PREDICTIVE DENTISTRY WORKS
In a predictive dentistry model, patient data, like history of cavities, gum disease, dietary habits, smoking status, and even jaw development, is fed into AI-powered software. These advanced systems analyze the information using algorithms to identify subtle patterns that may not be visible during a routine exam. The output is a personalized risk profile that highlights potential issues ranging from tooth decay and gum disease to more serious health risks.
For patients, the benefits are clear. Early detection of hidden or developing problems means fewer invasive treatments, reduced costs, and less discomfort in the long run. Instead of waiting for a tooth to decay or a gum infection to worsen, dentists can intervene early with targeted strategies. Predictive analytics also supports the creation of highly personalized treatment plans based on each individual's unique health profile. This means better outcomes with fewer complications and more efficient use of resources.
Another key benefit is improved communication. Visual tools and data visualizations make it easier for dentists to explain a patient's risk factors and treatment options. This empowers patients to understand their health better and make more informed decisions about their care.
Also read: 'We shouldn't use Mounjaro as a way to get skinny': Dr Alexandra Sowa
Consider, for example, a patient showing early gum inflammation with a family history of diabetes. A predictive model may flag them as high-risk, prompting timely blood sugar testing and possibly catching the disease before symptoms appear. In another scenario, predictive tools could warn a dentist about a child's jaw development patterns, indicating a need for early orthodontic intervention. Even when teeth appear healthy, patterns in enamel wear or bite pressure could signal future fractures or decay, allowing preventive measures to be put in place.
THE CHALLENGES OF PREDICTIVE DENTISTRY ANALYTICS
While promising, the adoption of predictive analytics in dentistry isn't without challenges. Patient data privacy is a critical concern, and clinics must ensure that sensitive health information is stored and used securely. Additionally, these predictive models are tools, not crystal balls. Their insights are based on probability and patterns, not certainties, and must be interpreted in conjunction with clinical judgment.
There are also concerns about equitable access. Advanced AI-powered tools are more commonly available in urban or high-end dental practices, potentially widening the gap between patients who can and cannot afford such technology. Bridging this gap will be essential to ensuring fair and inclusive healthcare access. Moreover, dentists need proper training to use these tools effectively. Understanding how to interpret predictive data and translate it into actionable care plans is vital for maximizing patient benefit.
Looking to the future, predictive analytics is set to become an integral part of dental care. As healthcare systems become more integrated, dentists may increasingly collaborate with general physicians to provide a fuller picture of patient health. Early signs of disease caught in the dental chair could lead to quicker referrals, timely diagnosis, and more comprehensive treatment plans. Ultimately, your next dental appointment might go well beyond routine care. With predictive analytics, it could become a gateway to understanding your broader health picture, helping to prevent not just cavities, but potentially serious medical conditions. Dentistry is becoming smarter, more proactive, and more personalized, and that's a win for both patients and practitioners.
Dr. Prafull Sabadra is an aesthetic and cosmetic dentist and founder of Dr. Sabadra's Advanced Dentistry Centre, Mumbai.
Also read: Are stress and anxiety damaging your teeth?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
a day ago
- NDTV
Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
New Delhi: Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Obesity injections may have less weight loss effect in reality: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
NDTV
2 days ago
- NDTV
Mounjaro Side Effects: From Nausea To Kidney Problems, Here Are All The Possible Harmful Effects
Quick Read Summary is AI generated, newsroom reviewed. Mounjaro (tirzepatide) is a weekly injectable drug for type-2 diabetes that aids weight loss by regulating appetite. Common side effects include nausea, diarrhea, and abdominal pain. Consult a doctor before use and monitor for potential interactions and side e Mounjaro is a brand name for tirzepatide, a prescription drug primarily used to manage type-2 diabetes. This once-weekly injectable drug helps maintain healthy blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Recently, it has gained attention in the realm of weight management. Mounjaro aids in weight loss by promoting feelings of fullness and reducing hunger, which contributes to a lower calorie intake. It is used widely by individuals who are overweight or obese, even those without diabetes, to shed weight more easily. While there are benefits to using Mounjaro, it can also cause side effects. Below are some of the most common side effects reported: Side effects of Mounjaro As with any medication, Mounjaro can cause side effects. Some of the most common side effects reported include: 1. Nausea This is the most frequently reported side effect and often decreases over time. Mounjaro slows down the emptying of the stomach which can cause nausea. 2. Diarrhea Some individuals may experience gastrointestinal issues such as diarrhea, which can subside as the body adjusts. 3. Vomiting Similar to nausea, vomiting can occur, especially when starting the medication. 4. Constipation Due to changes in appetite and reduced intake of calories, Mounjaro can cause constipation. Adding more dietary fibre to the diet may help elevate this issue. 5. Abdominal pain Discomfort in the stomach area is another potential side effect. These symptoms often subside as the body gets used to it. Serious side effects, although rare, can include pancreatitis, gallbladder issues, kidney problems, allergic reactions and severe gastrointestinal issues. It is crucial to seek medical attention immediately if you experience severe abdominal pain, changes in urination, or any signs of an allergic reaction. Safety tips to follow 1. Consult a healthcare professional Mounjaro is a prescription drug. Always speak to your doctor before starting Mounjaro. They can assess your medical history and determine if it's a suitable option for you. 2. Check blood sugar levels regularly If you have diabetes, regularly checking your blood sugar levels is essential, especially when starting Mounjaro. 3. Start with low doses Begin with a low dose to mitigate side effects and allow your body to adjust gradually. However, it is best to administer the dose prescribed by your doctor. 4. Follow a balanced diet While Mounjaro can aid in weight loss, pairing it with a healthy, balanced diet can help keep digestion healthy. 5. Stay hydrated Due to potential gastrointestinal effects, ensure you drink plenty of fluids to stay hydrated. 6. Be aware of potential interactions Check with your doctor if you are currently taking any medication to avoid any potential interactions. Keep track of any side effects you experience and attend regular check-ups with your doctor. It is advisable to undergo regular kidney function tests, liver function panels, and monitor for any abdominal symptoms while using this medication. Mounjaro is generally considered safe for use under medical supervision, especially for individuals who are overweight or obese. While it offers substantial benefits, understanding potential side effects and adhering to safety measures is crucial.
